Morgan Stanley Bio Atla, Inc. Call Options Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCAB
# of Institutions
83Shares Held
22.4MCall Options Held
10.7KPut Options Held
7.4K-
Soleus Capital Management, L.P. Greenwich, CT3.9MShares$8.04 Million0.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$3.88 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.65MShares$3.4 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$2.83 Million0.23% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.2MShares$2.46 Million0.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $74.8M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...